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Background: Dexamethasone is reported to induce both tumor-
suppressive and tumor-promoting eﬀects. The purpose of this
study was to identify the genomic impact of dexamethasone in
glioblastoma stem cell (GSC) lines and its prognostic value;
furthermore, to identify drugs that can counter these side eﬀects
of dexamethasone exposure.
Methods:We utilized 3 independent GSC lines with tumorigenic
potential for this study. Whole-genome expression proﬁling and
pathway analyses were done with dexamethasone-exposed and
control cells. GSCs were also co-exposed to dexamethasone and
temozolomide. Risk scores were calculated for most aﬀected
genes, and their associations with survival in The Cancer Ge-
nome Atlas and Repository of Molecular Brain Neoplasia Data
databases. In silico Connectivity Map analysis identiﬁed
camptothecin as antagonist to dexamethasone-induced negative
eﬀects.
Results: Pathway analyses predicted an activation of dex-
amethasone network (z-score: 2.908). Top activated canonical
pathways included “role of breast cancer 1 in DNA damage
response” (P=1.07E–04). GSCs were protected against
temozolomide-induced apoptosis when coincubated with dex-
amethasone. Altered cellular functions included cell movement,
cell survival, and apoptosis with z-scores of 2.815, 5.137, and
–3.122, respectively. CCAAT/enhancer binding protein beta
(CEBPB) was activated in a dose dependent manner specifically
in slow-dividing “stem-like” cells. CEBPB was activated in
dexamethasone-treated orthotopic tumors. Patients with high
risk scores had significantly shorter survival. Camptothecin was
validated as potential partial neutralizer of dexamethasone-
induced oncogenic effects.
Conclusions: Dexamethasone exposure induces a genetic pro-
gram and CEBPB expression in GSCs that adversely aﬀects key
cellular functions and response to therapeutics. High risk scores
associated with these genes have negative prognostic value in
patients. Our ﬁndings further suggest camptothecin as a po-
tential neutralizer of adverse dexamethasone-mediated eﬀects.
Key Words: dexamethasone, glioblastoma, glioblastoma stem
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G lioblastoma is the most common malignant primarybrain tumor in adults,1 with a median survival of
15.3 to 21.7 months.2 Neural, proneural, classical, and
mesenchymal subtypes have been described, whereof
mesenchymal glioblastoma are described as the most ag-
gressive.3 The transcription factor CCAAT/enhancer
binding protein beta (CEBPB) is proposed to be a master
regulator of mesenchymal programming in glioblastoma.4
Capillaries in glioblastoma do not evince the physio-
logical blood-brain barrier and thus exhibit increased
permeability leading to edema.5 Dexamethasone is the
clinical standard for treating vasogenic edema-induced
local mass eﬀects and elevated intracranial pressure in
glioblastoma.6
Although dexamethasone is eﬀective in managing
edema, its molecular impact remains controversial: it has
been reported to induce proliferation in glioblastoma
cell lines,7 while other studies demonstrated that it has
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inhibitory eﬀects on proliferation of human glioblastoma
cell lines in vitro.8 A rat model study generated the pro-
posal that dexamethasone reduces both the expression
and the response of vascular endothelial growth factor
(VEGF), thus reducing edema.9 Dexamethasone-
mediated induction of apoptosis in human glioblastoma
cell lines as well as its antitumor activity in xenografted
nude rats have been described,10 and it has also been
suggested that dexamethasone reduces invasiveness of
human glioblastoma cells in vitro and blood vessel in-
vasion in vivo through a MAPK phosphatase-1–depen-
dent mechanism.11 Furthermore, glioma growth was
reduced in mice following treatment with dexamethasone
or antiangiopoietin 2.12 Recently, however, Wong and
colleagues showed that glioblastoma patients who re-
ceived a dexamethasone dose >4.1mg/d had significantly
shorter OS than those who received r4.1mg/d. The
study attributed this finding to immunologic interference
in treatment efficacy.13 Thus, the drug’s impact on biol-
ogy is controversial.
Singh et al14 strongly supported the key role of the
cancer stem cell hypothesis15 in glioblastoma, whereby
glioblastoma stem cells (GSCs) appear to retain multiple
salient features of the original tumor and contribute to
therapeutic resistance and tumor recurrence. Since the
publication of that report, GSCs derived from human
tumors have become a reliable tool for investigating
glioblastoma biology in the laboratory. So far there are
no data on the impact of dexamethasone exposure on
GSCs. Therefore, we aimed to identify key genes and
molecular mechanisms regulated by dexamethasone in
patient-derived GSC lines. We further aimed to assess the
prognostic signiﬁcance of a risk score based on these al-
tered genes in glioblastoma patients and to identify clin-
ically relevant antagonists.
MATERIALS AND METHODS
Ethics Approvals
GSC lines were derived from MD Anderson Cancer
Center patients who gave written informed consent in
advance and in accordance with an MD Anderson in-
stitutional review board–approved protocol (LAB04-
0001).
All animal use complied with institutional and
governmental laws and regulations and was approved by
the MD Anderson institutional animal care and use
committee (protocol 00001100-RN00) in accordance with
the guidelines of the American Association for Labo-
ratory Animal Science.
Proliferation of Patient-derived GSCs
To obtain a robust representation of glioblastoma
(GBM), 3 independent MD Anderson patient-derived
GSC lines (GSC1, GSC3, and GSC6) were isolated and
cultured from surgical specimens as described else-
where.14,16 In brief, cells were grown in GSC medium
consisting of Dulbecco modiﬁed eagle medium (DMEM)/
F12 (Corning, Corning, NY) including L-glutamine
(Sigma, St Louis, MO), 1penicillin/streptomycin
(Corning), 1B27 without vitamin A (Life Technologies,
Carlsbad, CA), 20 ng/mL basic ﬁbroblast growth factor
(VWR, Radnor, PA), and 20 ng/mL epidermal growth
factor (EMD Millipore, Billerica, MA) at 371C in pres-
ence of 5% CO2 as deﬁned previously by Singh et al.
14
Cells were passaged according to standard protocols with
3 minutes exposure to Accutase cell detachment solution
(EMD Millipore) at 371C.
Differentiation Assays
GSCs were diﬀerentiated in tissue culture ﬂasks and
in chamber slides (Labtek, Scotts Valley, CA) and pre-
treated with poly-L-lysine (PLL) (Sigma) overnight at
371C. The 3 GSC lines were allowed to attach to PLL
coated plates. After 12 hours, the medium was changed to
diﬀerentiation medium containing DMEM, 1 pen-
icillin/streptomycin, and 10% fetal bovine serum
(Denville Scientiﬁc, Holliston, MA). The medium was
exchanged every 48 hours. Cells diﬀerentiated in ﬂasks
were harvested on day 7 with 3 minutes exposure to
0.25% Trypsin solution (Corning), whereas diﬀerentiated
cells in chamber slides were ﬁxed with 4% paraf-
ormaldehyde for 10 minutes at room temperature before
proceeding to immunoﬂuorescence analysis.
Flow Cytometry
GSC lines were cultured in GSC medium for pro-
liferation assays. After Accutase treatment, single cells
were ﬁxed with 4% paraformaldehyde for 10 minutes at
room temperature and were washed twice with
phosphate-buﬀered saline solution. Cells were per-
meabilized with permeabilization buﬀer containing 1%
bovine serum albumin, 0.1% Triton X-100, and 0.09%
sodium azide for 15 minutes at room temperature. Per-
meabilized cells were then incubated with mouse anti-sex
determining region Y-box 2 (Sox2), a stem cell marker
(R&D Systems, Minneapolis, MN); another stem cell
marker, rabbit anti-nestin (NES) (Thermo Scientiﬁc
Pierce, Waltham, MA); and cell proliferation marker
rabbit anti-Ki67 (Thermo Scientiﬁc Pierce) in per-
meabilization buﬀer for 30 minutes at room temperature.
After 3 washes with permeabilization buﬀer, species-
speciﬁc allophycocyanin-conjugated secondary antibodies
anti-mouse (BD Biosciences, San Jose, CA) and anti-
rabbit (Thermo Scientiﬁc Novex, Grand Island, NY) were
used for indirect labeling according to the manufacturer’s
protocol. Fluorescence-activated cell sorting (FACS)
analysis was performed with a Gallios ﬂow cytometer
(Beckman Coulter, Brea, CA: Flow Cytometry and Cel-
lular Imaging core facility, MD Anderson Cancer Cen-
ter). The gates for sorting were based on isotype control
samples for each GSC line. The FACS data were analyzed
with FlowJo software (version 10).
Western Blot Analysis
Total proteins were extracted from the three in-
dependent GSC lines in the presence of protease and
phosphatase inhibitors (Thermo Scientiﬁc Pierce) and
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analyzed with Western blotting for speciﬁc proteins.
Brieﬂy, each whole-cell extract (50 to 100 mg) was resolved
on a 10% to 12.5% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (Fisher BioReagents,
Pittsburgh, PA) and transferred to a nitrocellulose
membrane. The membranes were probed with mouse
anti-Sox2 (R&D Systems), rabbit anti-NES (Thermo
Scientiﬁc Pierce), rabbit anti-Ki67 (Thermo Scientiﬁc
Pierce), and mouse anti-glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (Abcam, Cambridge, MA) pri-
mary antibodies overnight at 41C. Rabbit anticleaved
PARP (Cell Signaling), was used as apoptosis marker.
The membranes were incubated with species-speciﬁc
horseradish peroxidase–conjugated secondary antibodies
for 1 hour at room temperature. The membranes were
exposed to Clarity Western ECL Substrate (BioRad,
Hercules, CA) and scanned with a c600 imaging system
(Azure Biosystems, Dublin, CA). Scanned images were
analyzed with cSeries Capture Software. Specific protein
bands in Western blots were quantified with ImageJ
software.
Immunofluorescence Analysis
Cells were diﬀerentiated for 7 days on PLL coated
Lab-Tek II Chamber slides (50,000 cells per chamber),
ﬁxed as described above, and stained with mouse anti-
GFAP (glial ﬁbrillary acidic protein) antibody and goat
anti-mouse rhodamine–conjugated secondary antibody
(both, Thermo Scientific Pierce). Nuclei were counter-
stained with 40,6-diamidino-2-phenylindole. Images were
taken with a DFC3000 G microscope (Leica, Buffalo
Grove, IL) using a 20 objective and analyzed with LAS-
X software.
Orthotopic Tumor Formation
Nine (33) male nude mice (strain nu/nu, 5wk old;
obtained from the Department of Veterinary Medicine
and Surgery at MD Anderson Cancer Center) were im-
planted with a nylon bolt in an orthotopic position 2mm
posterior and 1.5mm lateral to the bregma in the right
cerebral hemisphere. The animals were anesthetized
through this procedure, receiving ketamine intra-
peritoneally as described elsewhere.16 One week after
bolting, each animal was injected with GSC1, GSC3, or
GSC6 (1105) in DMEM (5 mL) over 5 minutes through
the bolt, again under anesthesia and with intraperitoneal
ketamine.16 Mice were killed with hypercarbia and de-
capitation at the earliest onset of neurological symptoms
and their brains were collected in formalin for paraﬃn
embedding. Embedded tumor-bearing brains were cut
into 5-mm slices and deparaﬃnized in xylene, rehydrated
in an alcohol series (100% to 70%) and double distilled
water, and stained with hematoxylin and eosin (H&E), all
according to standard protocols. H&E-stained slides were
imaged with an Olympus BX51 microscope (Olympus
USA, Center Valley, PA) using a 10 objective, and the
images analyzed with QCapture software.
Dexamethasone, Temozolomide, and
Camptothecin Treatment
A broad range of dexamethasone concentrations
have been used for in vitro studies,17 and the concen-
tration we used (50 mm) falls within this range.18 Single
cell suspension of GSCs after 3 minutes exposure to Ac-
cutase cell detachment solution (EMD Millipore) were
exposed for 6 days to GSC medium containing dex-
amethasone 50 mM (Sigma) or GSC medium alone as
control. Medium was exchanged daily. To validate the in
silico prediction in vitro, GSC 3 and 6 were exposed to 0,
25, 50, and 100 mm dexamethasone over 3 days under
stress of concomitant treatment with 500 mm of the al-
kylating chemotherapeutic agent temozolomide (Sigma).
Medium was exchanged daily. Total proteins were ex-
tracted and analyzed with Western blotting as described
above. GSCs exposed to dexamethasone for 5 days were
coexposed to 10 mM camptothecin19 for 24 hours and cells
were harvested for total RNA isolation followed by re-
verse transcriptase and quantitative polymerase chain
reaction (PCR).
Label Retention Analysis
GSC1 and GSC3 were exposed to 5 mM of CellTrace
carboxyﬂuorescein succinimide ester Cell Proliferation
substrate (Thermo Scientiﬁc Novex, Grand Island, NY)
for 20 minutes at room temperature followed by removal
of free dye from the solution as per the manufacturer’s
protocol and treated with 50 mM dexamethasone (daily
exchange) for 8 to 10 days. Cells underwent FACS sorting
for high versus low CFSE dye retaining cells. Gates for
FACS were set with negative and positive samples (CFSE
stained on the day of sorting).
RNA Isolation, Whole-Genome Expression
Profiling, Reverse Transcriptase and Real Time
PCR
RNA was isolated with Purezol RNA Isolation
Reagent (BioRad) according to the manufacturer’s pro-
tocol. After quality control, RNA was analyzed with the
Human Transcriptome 2.0 Microarray (Aﬀymetrix, Santa
Clara, CA) according to the producer’s standards (Mi-
croarray core facility, Department of Genetics, MD
Anderson Cancer Center). Probe cell intensity data
(.cel format) were uploaded and normalized across all 3
GSC lines, either treated with dexamethasone or un-
treated (controls), using the Expression Console software
(Aﬀymetrix) with gene level analysis. All gene conﬁdence
levels (core, extended, and full) were included in the
analysis, as recommended by the manufacturer. Ex-
pression proﬁles were analyzed with the Transcriptome
Analysis Console (Aﬀymetrix), employing a cutoﬀ of
±2.0 fold-change and a normalization z-score of Z2.0
as described in a previous publication.20,21 In brief, the z-
score adjusts data within a single probe. Values for in-
dividual genes are expressed as the standard deviation
from the normalized mean of zero.22
The selected genes were assessed with the ingenuity
pathway analysis platform (Qiagen, Valencia, CA) to
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predict dexamethasone-induced cellular functions, their
networks of upstream regulators and canonical pathways.
A heatmap of predicted upstream regulators and diﬀer-
entially expressed genes was generated with the Gene E
program (www.broadinstitute.org/).
Approximately 100 to 200 ng of total RNA were
used as template in reverse transcriptase reaction with
iScript cDNA synthesis kit (BioRad) as per manu-
facturer’s protocol. The cDNAs were then ampliﬁed with
SYBR Green-based PCR (BioRad) using CFX real-time
system. Data were analyzed with BioRad CFX manager
and 2DDCt values were plotted after normalization with
GAPDH (housekeeping gene), P-value were calculated by
2-tailed T-Test between samples. Gene speciﬁc primers
used were: GAPDH—forward: 50AAGGTGAAGG
TCGGAGTCAA30; reverse: 50AATGAAGGGGTCATT
GATGG30. CEBPB—forward: 50 CGTGTACACACGC
GTTCAG30; reverse: 50CTCTCTGCTTCTCCCTCTG
C30. Sox2—forward: 50 GCTTAGCCTCGTCGATGAAC30;
reverse: 50AACCCCAAGATGCACAACTC30. FKBP5—
forward: 50 GCGGAGAGTGACGGAGTC30; reverse: 50T
GGGGCTTTCTTCATTGTTC30. MT1X—forward: 50 GC
AAATGCAAAGAGTGCAAA30; reverse: 50CTTTGCA
GATGCAGCCCT30. TIMP4—forward: 50 ACGCCTTTTG
ACTCTTCCCT30; reverse: 50TTTCCATCACTGAGGAC
CTG30.
In Vivo Model
After tumor forming capacity of GSC3 was con-
ﬁrmed, we injected 10 mice with 1105 human GSC3 as
described above. Upon the day of the orthotopic in-
jection, 5 mice in each group were treated daily with 2mg/
kg (50 mg in 100 mL H2O) dexamethasone (Sigma Aldrich)
intraperitoneally, as described in previous publications.23
The 5 control animals received 100 mL H2O intra-
peritoneally daily. Animals mice were killed with hyper-
carbia and decapitation at the earliest onset of
neurological symptoms, in accordance with MD Ander-
son’s institutional animal research protocol. Some of the
brains were immediately collected in formalin for paraﬃn
embedding and later H&E and immunohistochemical
staining. Others were placed in collection solution and
then processed with a NeuroCult enzymatic dissociation
kit (Stemcell Technologies, Vancouver, BC, Canada) to
obtain orthotopic tumor cells for ex vivo expression
analysis.
Histopathologic Staining
Paraﬃn-embedded brains from the dexamethasone-
treated and control mice were cut into 5-mm slices,
mounted on slides, deparaﬃnized in xylene, rehydrated in
a descending alcohol series, and every 10th slide stained
with H&E according to standard protocols. To assess
CEBPB protein expression in the orthotopically im-
planted tumors, we stained tumor samples with a CEBPB
speciﬁc antibody (Abcam, San Francisco, CA), and in-
cubated overnight at 41C.
The slides were then incubated with polyclonal
secondary antibodies (Abcam) and exposed to peroxidase
(Abcam) and DAB substrate (Vector Laboratories, Bur-
lingame, CA) according to the manufacturers’ protocols.
Counterstaining with haematoxylin was performed with
standard procedures; ﬁnally, probes were pictured with an
Olympus BX51 microscope (Olympus USA) and images
were acquired using QCapture software.
Risk Score Calculation and Clinical Outcome
Analyses
Genes with Z3.5 fold-change in expression upon
dexamethasone exposure were analyzed for survival in the
patient databases of The Cancer Genome Atlas (TCGA)
and the Repository of Molecular Brain Neoplasia Data
(REMBRANDT). Small nucleolar RNAs were excluded,
as they are not present on the U133A microarray plat-
form. Cox regression coeﬃcient of each gene was calcu-
lated by using a Cox hazard model. A risk score (RS) was
calculated for each patient by using the following equa-
tion:
RS ¼
Xn
i¼1
bi:xi
where bi and xi are the Cox regression coeﬃcient and
expression levels of the ith gene of the signature.24 Using
median risk score as a cutoﬀ, patients were dichotomized
into high-risk and low-risk groups. Diﬀerence in overall
survival (OS) for the 2 groups was analyzed by the
Kaplan-Meier (KM) method with a 2-sided log rank test.
OS was deﬁned as the time between the date of pathologic
diagnosis and the date of death or the date of last clinical
follow-up visit. To evaluate the eﬀect of age and func-
tional impairment on the prognostic eﬀects of the gene
signature, we calculated the age and Karnofsky Perfor-
mance Score-adjusted hazard ratio in a multivariable Cox
regression model in the TCGA cohort. A P-value r0.05
was considered statistically signiﬁcant. Statistical analyses
were done by using R (version 3.2.2) and SPSS (version
22) software. Expression z-scores of individual genes (the
gene expressions have been z-scored for each sample over
the entire gene platform panel)25 in speciﬁc molecular
subgroups of GBM, that is, mesenchymal and proneural
were obtained from GBM-BioDP software (http://gbm-
biodp.nci.nih.gov). For single gene clinical outcome,
patients were dichotomized based on median expression
z-score25 and KM curve analysis were performed using
GraphPad Prism 6 software. P-value is calculation is
based on Gehan-Breslow-Wilcoxon test.
Connectivity Map Analysis
The genes identiﬁed as being regulated by dex-
amethasone in GSCs were then analyzed by the pattern-
matching Connectivity Map platform to identify
therapeutic agents that could potentially counteract the
predicted dexamethasone-induced oncogenic eﬀects. The
upregulated and downregulated genes (mRNA, fold-
change r2.0 or Z2.0 in microarray) in their rank or-
der were uploaded to Connectivity Map (http://
www.broadinstitute.org), where a collection of genome-
wide expression proﬁles from human cell lines treated
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with bioactive agents is archived.26 The details of Con-
nectivity Map analysis are described elsewhere.27,28 In
brief, the platform creates a “connectivity score” of col-
lected and uploaded data where upregulation yields a
positive score and downregulation a negative score (0 if
no change). Respecting means of observed results, num-
ber of available cell lines, P-values, speciﬁcity, percentage
of non-null results, and enrichment scores, the program
ranks the results. The enrichment score displays the de-
gree to which a set is overrepresented at the extremes
within a ranked list.29
RESULTS
Stem Cell Properties and Orthotopic Tumor
Formation are Confirmed in Human
Glioblastoma-derived Cells
First, we sought to establish that our patient-derived
cell lines GSC1, GSC3, and GSC6 had stem cell features
and the potential to diﬀerentiate. FACS results show that a
very high percentage of cells from all 3 GSC lines expressed
the stem cell markers Sox2 and NES and the proliferation
marker Ki-67 (KI67) when cultured in GSC medium
(Supplemental Figure 1A i–iii, Supplemental Digital
Content 1, http://links.lww.com/JNA/A36). We then ex-
posed GSCs maintained in GSC medium to differentiation
conditions. Western blot results show significantly lower
protein levels of stem cell and proliferation markers under
differentiation conditions than under proliferation con-
ditions (Supplemental Figure 1B, Supplemental Digital
Content 1, http://links.lww.com/JNA/A36). Immuno-
fluorescence analysis using antibody against differentiation
marker GFAP show expression of the marker in all three
GSC lines cultured in differentiation medium (Supple-
mental Figure 1Ci–iii, Supplemental Digital Content 1,
http://links.lww.com/JNA/A36). All 3 GSC lines, when
implanted at orthotopic locations in mouse brains, gave
rise to xenograft tumors which bore hallmarks of glio-
blastoma, such as high cellularity, areas of necrosis, and
hypervascularization (Supplemental Figure 1D i–iii, Sup-
plemental Digital Content 1, http://links.lww.com/JNA/
A36).
Genes Associated With Cell Proliferation and
Movement are Most Significantly Affected by
Dexamethasone Exposure in GSCs
Having conﬁrmed the identity and tumorigenic
potential of these GSC lines, we proceeded to assess the
global impact of dexamethasone at the molecular level by
microarray proﬁling of dexamethasone-treated GSCs
(n=3) and their respective controls (n=3). This analysis
of the expression proﬁle data identiﬁed 333 altered genes,
290 upregulated and 43 downregulated (Aﬀymetrix Hu-
man Transcriptome Array 2.0 Probeset IDs of
dexamethasone-regulated genes in GSC1, GSC3, and
GSC6 with cutoﬀ >2.0 fold-change in Supplemental
Table S1, Supplemental Digital Content 2, http://links.
lww.com/JNA/A37). Pathway analysis of the altered
genes in our dataset predicted that the dexamethasone-
regulated network was activated (activation z-score 2.908,
P=4.23E–08; Figs. 1A, B), providing an unbiased vali-
dation of our expression profile data. Furthermore, genes
associated with this dexamethasone network alone had
significant activating impact on cellular functions such as
proliferation (based on 30 genes; P=6.14E–11),
cell movement (based on 20 genes; P=3.35E–09), and
inhibition of cell death (based on 29 genes; P=3.03E–1;
Fig. 1B).
Network analysis of the entire data set of dexa-
methasone-induced genes showed signiﬁcant activation
of cell survival (z-score 5.137, P=1.12E–08; Fig. 1C),
decreased apoptosis (z-score –3.122, P=1.31E–06;
Fig. 1D), and increased movement (z-score 2.815,
P=1.61E–04; Fig. 1E). Top affected canonical pathway
was “Role of Breast Cancer (BRCA)1 DNA Damage
Response” (z-score 1.633, P=1.07E–04). The in vitro
validation of in silico prediction showed a decrease
in cleaved PARP with increasing concentrations of
dexamethasone indicating a protective effect against
DNA damage upon concomitant treatment with 500 mM
Temozolomide in GSC3 and GSC6 (Fig. 1F).
As an additional ﬁlter to predict cellular functions
most aﬀected by dexamethasone exposure, we collated a
list of regulators (z-score >±2.0) whose functional
status was determined by downstream gene levels in our
expression data in dexamethasone-treated versus control
cells (Fig. 2A, Supplemental Tables S1, Supplemental
Digital Content 2, http://links.lww.com/JNA/A37 and
S2, Supplemental Digital Content 3, http://links.
lww.com/JNA/A38 ). The cumulative eﬀect of these up-
stream regulators and their respective downstream genes
were then used to predict cellular functions by using
an activation z-score of ±3.0 or more as cutoﬀ.
In this analysis, hepatocyte growth factor (HGF; activa-
tion z-score 3.572, P=1.22E–04; Fig. 2B), VEGF (acti-
vation z-score 3.335, P=8.07E–07) and VEGFA
(activation z-score 3.13, P=6.82E–06; Fig. 2C), and es-
trogen receptor 1 (ESR1; activation z-score 3.187,
P=3.39E–05; Fig. 2D) were the top activated regulatory
networks, and nuclear protein transcriptional regulator 1
(NUPR1; activation z-score 3.13, P=6.82E–06; Fig. 2E)
was the top inhibited network. All activated upstream
regulators, together with their downstream target genes,
were predicted to induce activation of cell movement and
survival (Fig. 2B–D). The top inhibited upstream regu-
lator (NUPR1) and its downstream targets (Fig. 2E), also
predicted to induce activation of cell movement and
survival. Interestingly CEBPB was predicted to be upre-
gulated by dexamethasone exposure (activation z-score
1.69, P=7.33E–043; Supplemental Figure 2, Supple-
mental Digital Content 4, http://links.lww.com/JNA/
A39).
CEBPB, A Master Regulator of Mesenchymal
Programming in Glioblastoma is Activated by
Dexamethasone
To validate the predicted upregulation of CEBPB
upon exposure to dexamethasone, we exposed GSC1
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FIGURE 1. Apoptosis is inhibited and survival is activated upon dexamethasone exposure. A, Fold-changes of gene expression in
the dexamethasone network predicted its activation status. Their respective associations (+) with the cellular functions (1) pro-
liferation, (2) cell death, and (3) cell movement are shown. B, This schematic representation shows the dexamethasone network,
the genes involved in its activation, and its predicted impact on cellular functions. Numbers under the gene names indicate the
fold-change in expression. C–E, Individual genes contributing to the activated state of cell survival (C), the inhibited state of
apoptosis (D), and the activated state of cell movement (E) in GSCs in response to dexamethasone are represented schematically.
Numbers under the gene names indicate the fold-change in expression. Genes and cellular functions are labeled and color coded.
A color index is shown at the bottom. F, Network analysis for canonical pathway affected by dexamethasone shows “role of
BRCA1 in DNA damage response” with z-score 1.633 as top result (i). Scans of Western blots of whole-cell extracts of GSC3 and
GSC6 treated with different concentrations of dexamethasone over 3 days under DNA damage stress of concomitant treatment
with 500 mM Temozolomide and probed with an antibody against cleaved PARP as marker of apoptosis (GAPDH is loading
control) (ii). Quantification of relative cleaved PARP amounts in Western blots (shown in ii) normalized with GAPDH (iii). BRAC1
indicates breast cancer 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSC, glioblastoma stem cell.
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AB C
D E
FIGURE 2. Oncogenic networks are activated by dexamethasone. A, Heatmap shows genes and their association with upstream
regulators with activation status z-scores Z2.0. The color intensity bar above the heatmap represents the range of fold-change of
gene expression: red as upregulation and blue as downregulation. B, Schematic of the HGF network (activation z-score 3.572) with
the genes associated with this top activated upstream regulator and their biological implications. C, Schematic of the VEGF
(activation z-score 3.335) and VEGFA (activation z-score 3.31) networks with the genes associated with this top activated upstream
regulator and their biological implications. D, Schematic of the ESR1 network (activation z-score 3.187) with the genes associated
with this top activated upstream regulator and their biological implications. E, Schematic of the NUPR1 network (activation z-score
4.041) with the genes associated with this top activated upstream regulator and their biologic implications. Genes and cellular
functions are labeled and color coded. A color index is shown at the bottom. ESR1 indicates estrogen receptor 1; HGF, hepatocyte
growth factor; NUPR1, nuclear protein transcriptional regulator 1; VEGFA, vascular endothelial growth factor A.
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FIGURE 3. The transcription factor C/EBPbeta (CEBPB), a master regulator of the most malignant subtype of glioblastoma is activated
upon dexamethasone exposure in vitro, ex vivo, and in vivo and dexamethasone treated thus CEBPB expressing cells slower division
rate as indicator for cell “stemness.” A, Relative expression levels of CEBPB in GSC1 upon exposure to 50, 100, and 200mM
dexamethasone for 6 days. B, Relative expression levels of CEBPB in GSC3 upon exposure to 50, 100, and 200mM dexamethasone for
6 days. C, Schematic of the experiment with CFSE labeling to determine cell division rates as a readout of stemness properties of GSCs
upon 8 to 10 days exposure to 50mM dexamethasone. D, CFSE labeled GSC1 cells treated with 50mM dexamethasone over 8 to 10
days selected for fast-dividing and slow-dividing subpopulations show a significant upregulation of CEBPB in slow-dividing cells upon
exposure to 50mM dexamethasone over 8 to 10 days. E, CFSE labeled GSC1 cells treated with 50mM dexamethasone over 8 to 10
days selected for fast-dividing and slow-dividing subpopulations show a significant upregulation of CEBPB in slow-dividing cells upon
exposure to 50mM dexamethasone over 8 to 10 days. F, Expression level analysis of GSC3 ex vivo derived orthotopic tumor cells
shows a significant increase of CEBPB expression levels upon exposure of tumor bearing mice to 2mg/kg dexamethasone daily for 4
weeks. G, immunohistochemistry staining with specific antibodies against CEBPB confirms the increase of CEBPB expression upon
exposure of tumor bearing mice to 2mg/kg dexamethasone. Red box: Area of 40x magnification. Brown nuclei are positive for
CEBPB. P-values are displayed above the compared samples in each graph. GSC indicates glioblastoma stem cell.
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and GSC3 cells to varying doses of dexamethasone for 6
days. Our results from quantitative real time PCR show
a dose dependent increase in CEBPB levels with R2
values of 0.96 and 0.91 in GSC1 and GSC3, respectively
(Figs. 3A, B). To further elucidate impact of dex-
amethasone on CEBPB levels in speciﬁc cell populations
within GSC cultures, namely CFSE high (slow-dividing
“stem-like” cells, express high levels of Sox2 (data not
shown)) and label low (fast dividing “non-stem–like”
cells), GSC1 and GSC3 cells were labeled with CFSE dye
and treated with 50mM dexamethasone over 8 to 10 days
and sorted for low (fast dividing) and high (slow dividing)
subpopulations (Fig. 3C). Real time PCR data show en-
dogenous levels of CEBPB is higher in CFSE high cells, a
trend which was maintained upon dexamethasone ex-
posure (Figs. 3D, E). CEBPB expression levels in ex vivo
isolated tumor cells showed a significant upregulation
upon treatment of mice with 2mg/kg dexamethasone over
4 weeks (Fig. 3F). Immunohistochemistry staining against
CEBPB protein confirmed this increase in tumor bearing
sections of dexamethasone-treated mice brains (Fig. 3G).
Patients With High Risk Scores for
Dexamethasone-induced Genes have Poorer
Prognosis and Dexamethasone-induced
Upregulation of Genes Included in the Score
Confirmed
Applying a most stringent cutoﬀ of >3.5 fold-
change identiﬁed 15 genes upregulated by dexamethasone
in GSCs (Table 1). To assess the clinical translatability of
these genes, we calculated the risk scores for each gene
as described in Methods. These scores were then
applied to discovery (TCGA, N=515) and validation
(REMBRANDT, N=178) data sets to identify each of
these glioblastoma patients as either high or low risk.
Strikingly, Kaplan-Meier analyses showed a signiﬁcant
survival diﬀerence between high-risk and low-risk groups
(Fig. 4). Median survival durations for patients with high
versus low risk score were 12.8 versus 16.7 months in the
TCGA cohort (N=515, P<0.001) and 13.1 months
versus 17.0 months in the REMBRANDT cohort
(N=178, P=0.015; Figs. 4A, B). The multivariate Cox
regression analysis of the TCGA cohort (hazard ratio,
1.92; 95% [conﬁdence interval] CI, 1.26-2.93; P=0.002)
showed that our risk score is a valid predictor of survival
independent of age (hazard ratio, 1.02; 95% CI, 1.01-1.03;
P<0.001) and Karnofsky Performance Score (hazard
ratio, 0.98; 95% CI, 0.97-0.99; P<0.001). The dex-
amethasone dependence of FKBP5, MT1X, and TIMP4,
3 representative genes predicted in the 2 databases, are
validated by real time PCR in vitro in GSC1 (Fig. 4C)
and GSC3 (Fig. 4D).
Identification and Validation of Camptothecin
as Neutralizer of Dexamethasone-induced
Genes In Vitro
The dexamethasone-regulated genes with expression
fold-change r2.0 or Z2.0 were assessed with Con-
nectivity Map, an archive of genome-wide expression
proﬁles from human cell lines treated with bioactive
agents; this archive can be used to identify interactions
between these agents and genes. This analysis was un-
dertaken to identify therapeutics that could potentially
counteract adverse gene expression changes induced by
dexamethasone. We identiﬁed therapeutics with enrich-
ment scores up to 0.992; the top-ranked compound was
camptothecin (Fig. 5A, Supplemental Table S3, Supple-
mental Digital Content 5, http://links.lww.com/JNA/
A40). The enrichment score reﬂects the degree to which a
set is overrepresented at the extremes within a ranked list.
To test potential antagonistic properties of camptothecin
to dexamethasone-induce alterations, we exposed GSC1
and GSC3 to camptothecin for 24 hours (a time point at
which we did not detect signiﬁcant amount of cell death.
Supplemental Figure 3, Supplemental Digital Content 6,
http://links.lww.com/JNA/A41) after these cells were pre-
exposed to dexamethasone for 5 days. Real time PCR data
show a signiﬁcant decrease in FKBP5 and MT1X levels in
cells co-exposed to camptothecin and dexamethasone as
compared with cells treated with dexamethasone alone
(Figs. 5B, C). Further analysis of TCGA expression data
show that FKBP5 and MT1X genes are highly expressed
in the mesenchymal subgroup (Figs. 5D, F). When the
proneural subgroup of patients were further subclassiﬁed
into high and low groups, the high group of patients has
signiﬁcantly poorer clinical outcome (Figs. 5E, G).
DISCUSSION
This preclinical study demonstrated that dex-
amethasone altered genes predicted to promote onco-
genic pathways in GSCs. High risk scores associated
with genes most responsive to dexamethasone exposure
were then found to be prognostic for poor outcome in 2
TABLE 1. Genes With >3.5 Fold-Change in TCGA and
REMBRANDT GBM Patient Cohorts
Gene
Fold-
change
Beta-coeﬃcient
Score TCGA
Beta-coeﬃcient Score
REMBRANDT
FKBP5 7.47 0.097 0.038
PRKAA2 5.87 0.086 0.395
PCDHB8 5.86 0.001 0.247
ABCA5 4.84 0.218 0.188
XRCC2 4.70 0.185 0.043
BRCA2 4.61 0.056 0.044
LIFR 4.57 0.167 0.198
LRRTM2 4.44 0.137 0.285
ITGA6 4.33 0.098 0.208
NEFL 4.33 0.021 0.085
MT1X 3.97 0.041 0.311
PCDHB12 3.61 0.03 0.066
ALDH7A1 3.59 0.056 0.1
TIMP4 3.55 0.007 0.129
CHD7 3.52 0.204 0.13
TCGA indicates The Cancer Genome Atlas; REMBRANDT, Repository of
Molecular Brain Neoplasia Data.
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independent clinico-genomic glioblastoma cohorts. This
is potentially of clinical importance, as dexamethasone is
widely used in glioblastoma patients to treat edema and
associated increased intracranial pressure during the
perioperative period. Further, analysis of altered genes
with Connectivity Map identiﬁed United States Food
and Drug Administration (FDA) approved drugs that
can counter these adverse dexamethasone-induced ef-
fects while potentially preserving the beneﬁcial anti-
edema eﬀects.
Upstream regulatory networks identiﬁed by this
work are well known in the pathogenesis of glio-
blastoma. HGF has been shown to be involved in epi-
thelial-to-mesenchymal transition through binding to
the receptor tyrosine kinase c-MET, not only in em-
bryogenesis but also in invasiveness of glioblastoma,
because of its potent induction of mesenchymal tran-
sition in epithelium-driven cells.30 A recent clinical trial
(phase II) investigated the antitumor activity of an anti-
HGF antibody: though no signiﬁcant advantage could be
FIGURE 4. Glioblastoma patients with high risk score for dexamethasone-induced genes have poorer prognosis. A, Kaplan-Meier
curve analysis of the TCGA glioblastoma cohort (n = 515). Median survival of glioblastoma patients with a high risk score (red) was
12.8 months, whereas that of patients with a low risk score (green) was 16.7 months (P<0.001). B, Kaplan-Meier curve analysis of
the REMBRANDT glioblastoma cohort (n = 178). Median survival of glioblastoma patients with a high risk score (red) was 13.1
months, whereas that of patients with a low risk score (green) was 17.0 months (P=0.015). C and D, Real time PCR for FKBP5,
MT1X, and TIMP4, members of dexamethasone-induced gene signature, in GSC1 and GSC3 with and without dexamethasone
exposure. P-values are displayed above the compared samples in each graph. GSC indicates glioblastoma stem cell; PCR,
polymerase chain reaction; REMBRANDT, Repository of Molecular Brain Neoplasia Data; TCGA, The Cancer Genome Atlas.
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FIGURE 5. Identification and validation of camptothecin as neutralizer of dexamethasone-induced effects in GSC. A, A list of top 10
therapeutics identified by connectivity map analysis based on dexamethasone-induced genomic profiles. The ranking was automatically
calculated, respecting mean observed values, number of cell lines available in the database, enrichment score, P-value, specificity, and
percentage of non-null results. B and C, In vitro exposure of GSCs with 10mM camptothecin and 50mM dexamethasone (alone and in
combinations), relative expression levels of FKBP5 and MT1X, 2 representative genes of the dexamethasone-induced oncogenic gene
network in GSC1 and GSC3. P-values are displayed above the compared samples in each graph. D and F, Expression of FKBP5 and
MT1X in mesenchymal and proneural subgroups of GBM patients in TCGA database. E and G, Kaplan-Meier curve analysis of the
proneural TCGA glioblastoma cohort (n=113). E, Median survival of proneural glioblastoma patients with a high FKBP5 expression is
7.33 months, whereas that of patients with a low FKBP5 expression is 16.75 months (P=0.0065). G, Median survival of proneural
glioblastoma patients with a high MT1X expression is 6.93 months, whereas that of patients with a low MT1X expression is 13.47
months (P=0.045). GSC indicates glioblastoma stem cell; TCGA, The Cancer Genome Atlas.
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shown in patients with recurrent glioblastoma,31 HGF’s
contribution to glioblastoma malignancy is unquestioned.
As a response to tissue hypoxia, the hypoxia-inducible
factor 1 acts as a transcription factor, controlling the ex-
pression of VEGF.32,33 Both VEGF and hypoxia-inducible
factor 1a have been shown to signiﬁcantly promote both
angiogenesis and invasion in glioblastoma.34 VEGFA, 1 of
5 VEGF subtypes, has been shown to be a prognostic in-
dicator for brain tumor patients.35 Given that vascular
proliferation is a key component of glioblastoma biology
and that VEGF expression levels directly correlate with
tumor malignancy and hence inversely with prognosis, the
anti-VEGF antibody bevacizumab has been approved by
the FDA for treatment of recurrent glioblastoma.36,37 The
role of estrogen receptors (ESRs) in glioblastoma remains
controversial: some evidence shows that ESRs are de-
creased in high-grade gliomas, while ESR expression levels
correlated negatively with tumor diﬀerentiation.38 The ESR
antagonist tamoxifen was shown to induce cell death in
glioma cells39 and has been proposed as a potential che-
motherapeutic agent in temozolomide-resistant glio-
blastoma.40 Our results provide a potential molecular basis
for this indication of tamoxifen, especially given that most
patients with recurrent glioblastoma are further exposed
to dexamethasone. NUPR1, the most inhibited dexa-
methasone-dependent upstream regulator we found, is in-
volved in a variety of stress-related functions in noncancer
conditions41 and as a tumor suppressor in prostate can-
cer.42 Our discovery of its potential involvement in glio-
blastoma is novel. The dose dependent increase in CEBPB
(both in vitro and in vivo) upon dexamethasone exposure, a
known regulator of mesenchymal program in GBM, is in-
dicative of a potential mesenchymal shift in tumor cells
(speciﬁcally in stem-like cells), which may contribute to
poorer outcome of patients.
In our screen, the cellular functions most aﬀected by
dexamethasone were activation of cellular survival and
migration as well as inhibition of cellular apoptosis, all
functions well known to drive glioblastoma patho-
genesis.43,44 DNA repair associated genes such as the tu-
mor suppressor BRCA1 are known to be increased upon
treatment with temozolomide.45 Interestingly, the activa-
tion of BRCA1 DNA damage response was the top af-
fected canonical pathway in our screen. The functional
readout of dexamethasone and temozolomide cotreat-
ment, however, showed a decrease of apoptosis with in-
creasing concentrations of dexamethasone. The upstream
regulatory networks contributing to these changes are
known to contribute to glioblastoma malignancy. These
preclinical ﬁndings are of importance as they oﬀer a
possible explanation for recent ﬁndings by Wong et al13
that glioblastoma patients who received higher dex-
amethasone doses had signiﬁcantly shorter OS than those
who received lower doses. Kaplan-Meier analysis of the
risk scores associated with the most dexamethasone-
responsive genes in our work supports a potentially
dexamethasone-dependent signiﬁcant survival diﬀerence
in the 2 most exhaustive clinical databases, TCGA and
REMBRANDT. That this prognostic association remains
signiﬁcant after multiple corrections indicates the robust-
ness of our screen and the possible distinct biological
mechanism induced by dexamethasone that mediates a
survival disadvantage, given that the vast majority of
patients might have been under dexamethasone treatment
when samples for the 2 databases were obtained. How-
ever, it appears likely that patients to whom larger doses
of dexamethasone were administered had larger tumor
and edema burden.
It remains unclear whether the described adverse
eﬀects of dexamethasone are due to its glucocorticoid or
drug speciﬁc eﬀect. Comparison with another cortico-
steroid would shed light on what is leading to the
changes in gene transcription. However, the fact that
cerebral edema is currently mainly treated with dex-
amethasone, an ethical dilemma might occur to test
other steroids’ eﬀects. Dexamethasone is essential not
only for acute treatment of edema in glioblastoma but
also as a long-term adjuvant for chemotherapy and ra-
diation therapy.46 Identiﬁcation of the FDA-approved
camptothecin by our enrichment analysis suggests a
potential route for future investigations to identify the
drug’s potential to reduce unwanted dexamethasone ef-
fects. Our in vitro results suggest that, as predicted in
silico, short-term exposure of camptothecin is able to
counter dexamethasone eﬀects at least partially. How-
ever, the presented evidence that dexamethasone in-
creases tumor cell survival is based on gene analysis, cell
survival and proliferation in vitro. To provide strong
evidence that dexamethasone increases tumor cell sur-
vival, both the size of orthotopic tumors and orthotopic
tumor bearing animals’ survival upon dexamethasone
treatment remain to be evaluated. In brief, these ﬁndings
resulting from an in vitro screen warrant further inves-
tigation in an in vivo model to uncover a deﬁnitive
mechanism.
In summary, our GSC data shine light on the in-
triguing controversy of dexamethasone-induced eﬀects
in cancer biology and provide novel insight into the
potential molecular mechanisms of these eﬀects. We
demonstrate that dexamethasone induces a gene sig-
nature that is a signiﬁcant predictor of poor prognosis in
glioblastoma patients. It is conceivable that neutralizing
dexamethasone-induced oncogenic eﬀects, for example,
with camptothecin, may become an integral part of
glioblastoma therapy. The data presented here may
represent a stepping stone to improving glioblastoma
treatment and prolonging patient survival.
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